INTRODUCTION
Protein C is a vitamin K-dependent glycoprotein that circulates in blood in a zymogen form (1) (2) (3) . Purified preparations of both human and bovine protein C are readily converted to a serine protease called activated protein C (APC).' This reaction is catalyzed by trace amounts of a-thrombin (3, 4) . Recently, this reaction has been shown to be greatly accelerated by a cofactor isolated from endothelial cells (5) (6) (7) .
Previous work from our laboratory, as well as several others, has clearly demonstrated that APC exhibits anticoagulant activity through its selective inactivation of Factor Va and Factor Vllla by limited proteolysis (4, 8, 12) . Furthermore, recent studies suggest a physiological role for APC in promoting fibrinolysis (13) . Thus, protein C apparently plays a critical role in blood coagulation, and its congenital deficiency, hypothetically, would result in a hypercoagulable state with episodes of thrombosis. Indeed, Griffin and his colleagues (14) have identified and characterized a family with a recurring thrombotic disease associated with an apparent plasma protein C deficiency.
Although a considerable amount of information has accumulated on the mechanism of action of APC, relatively little is known regarding the mechanism whereby APC is regulated in plasma. Recently, Marlar and Griffin (15) proposed that the molecular basis of the combined Factor V/VIII deficiency disease was due to a congenital deficiency of a plasma inhibitor to APC. In preliminary experiments, we observed no significant difference in the rate at which the anticoagulant activity of human APC was neutralized in plasma obtained from normal individuals and two unrelated patients with combined Factor V/VIII deficiency disease (16) . We now have expanded this study to include four patients, and in this article we present evidence that the functional levels of the putative APC inhibitor in normal and combined factor V/VIII-deficient plasma samples are essentially identical.
METHODS
Sepharose 4B, QAE-Sephadex A50, SP-Sephadex C-50, Sephadex G-150, Sephadex G-50, Sephadex G-25, activated CH-Sepharose, protein A-Sepharose CL-4B, and low molecular weight sodium dodecyl sulfate (SDS) electrophoresis standard proteins were products of Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, NJ. Electrophoresis-purity acrylamide, bisacrylamide, N,N,N',N'tetramethylenediamine, ammonium persulfate, and agarose (standard low-mr) were obtained from Bio-Rad Laboratories, Richmond, CA. Kaolin (acid-washed) was purchased from Fisher Scientific Co., Fair Lawn, NJ. Benzamidine hydrochloride, diisopropyl fluorophosphate (DFP), and 4-vinyl pyridine were purchased from Aldrich Chemical Co., Inc., Milwaukee, WI. SDS was obtained from Gallard-Schlesinger, Carle Place, NY. Lithium heparin (150 U. S. Pharmacopeia U/mg) was obtained from Riker Laboratories, Inc., Northridge, CA. D-Phenylalanyl-Lpipecolyl-L-arginyl-p-nitroanilide (S-2238) was obtained from Ortho Diagnostics, Inc., Raritan, NJ. Freund's incomplete and complete adjuvant were purchased from Difco Laboratories, Detroit, MI. Carrier-free sodium '2I in dilute NaOH (506 mCi/ ml) was purchased from New England Nuclear, Boston, MA. Sequenator reagents (Sequanol grade) and 1,3,4,6-tetrachloro3a,6a-diphenyl glycoluril (lodo-gen) were supplied by Pierce Chemical Co., Rockford, IL. Heparin-Sepharose was prepared as described (17) . Human brain cephalin was prepared according to Bell and Alton (18) . Purified rabbit IgG was purchased from Pel-Freeze Biologicals, Rogers, AR. Pansorbin, and rabbit antisera directed against human a,-antitrypsin, antithrombin III, a2-macroglobulin, Cl inactivator, and inter-atrypsin inhibitor were purchased from Calbiochem-Behring Corp., American Hoechst Corp., La Jolla, CA. Rabbit antiserum against human a2-antiplasmin was kindly provided by Dr. Nubuo Aoki, Jichi Medical School, Tochigi-ken, Japan. Plasma was prepared from normal individuals and combined Factor V/VIII-deficient patients by withdrawing nine parts of whole blood from the antecubital vein into polyethylene tubes containing one part 3.8% sodium citrate, followed by centrifugation at 2,500 g for 15 min at room temperature. Citrated plasma from five normal individuals was pooled and served as a normal reference plasma. Plasma samples from clinically-defined, combined Factor V/VIII-deficient patients were obtained through the courtesy of Dr. P. M. Mannucci (patient A), Dr. Maribel Clements (patient B), and Dr. Kenneth Smith (patients C and D). Dr. Smith provided plasma samples from two combined Factor V/VIII-deficient siblings (patient C and D). In the four samples of Factor V/VIII-deficient plasma obtained, the Factor V activity ranged from 13 -to 15% of normal, whereas Factor VIII:C activity ranged from 8 (19) , and were found to be 7-14% of normal. In addition, the Factor V antigen levels of these patients' plasma, as determined by radioimmunoassay (20) , ranged from 9 to 27% of normal. All plasma samples used in this study were tested for inhibitor activity within 6 mo after venipuncture. In one case (patient B), the plasma was tested within 12 h after venipuncture.
Amino acid analyses were carried out by standard procedures (21) (22) (23) (27) . Phenylthiohydantoin amino acids were identified and quantitated by high pressure liquid chromatography (28, 29) .
SDS-polyacrylamide gel electrophoresis (PAGE) was performed in glass tubes (6 X 100 mm) as previously described (2) . The tube gels were run at room temperature at a constant current of 5 mA/gel. The gels were stained for protein and carbohydrate as described (2) . The distribution of radioactivity in tube gels was determined by slicing the gel into 1-mm sections (Joyce-Loebl gel slicer) followed (20, 000) , and a-lactalbumin (14, 400 Ganrot (33) . Autoradiography was performed essentially as described by Swanstrom and Shank (34) . Kodak X-Omat AR film (Eastman Kodak Co., Rochester, NY) was inserted between the dried slab gle and a DuPont Cronex Lightning-Plus intensifying screen (DuPont Co., Instrument Products Div., Wilmington, DE) in a Kodak x-ray exposure holder. Films were exposed for 1-4 h at -70°C, and developed at room temperature according to the manufacturer.
Radioiodination was performed according to a slight modification of the technique described by Salacinski et al. (35 Proteins. Human protein C and human a-thrombin were prepared as previously described (3). Human APC was prepared as follows. 300 Mg of human a-thrombin (in 200 Ml of TBS) was added to 5 ml of TBS containing 5 mg of human protein C. The mixture was incubated in a plastic tube. for 3 h at room temperature. The incubation mixture was chilled to 4°C and applied to a column of SP-Sephadex C-50 (1.6 X 10 cm) previously equilibrated at 4°C with TBS. After sample application, the column was eluted with TBS at a rate of 0.5 ml/min. Under these conditions, human APC eluted in the unadsorbed fraction, while thrombin remained tightly bound to the resin. Aliquots of the human APC pool were stored at -70°C until further use. 100 pl of the APC pool (33 ug) , when incubated at 370C with 300 Al of 0.4% fibrinogen in TBS, failed to produce a clot in 3 h, indicating the absence of thrombin. The isolated APC, however, possessed potent anticoagulant activity as judged by its ability to prolong the kaolin-cephalin clotting (KCCT) time of human plasma. In a typical experiment, 1 Ag of purified human APC increased the KCCT of normal plasma from -50 s to >1,500 s. As observed in previous experiments, the anticoagulant activity of the isolated human APC was totally inhibited by DFP (3).
Human antithrombin III was purified by the procedure described by Mahoney et al. (36) . The warmed to room temperature and applied to the affinity resin, previously equilibrated at room temperature with TBS. After sample application, the column was eluted with ten column-volumes of TBS:1 M NaCl. The antibody was eluted from the affinity column with one column-volurne of 0.1 M glycine-HCI (pH 2.5). The affinity-purified antibody was collected in plastic tubes containing an appropriate amount of 0.5 M Tris-HCl (pH 8.5) that immediately adjusted the pH of the eluant to 7.5. The affinity-purified antibodies were dialyzed at 4°C against TBS:0.02% NaN3 and stored at 40C.
Neutralization of APC in various plasmas. The inhibition of APC in normal plasma and combined Factor V/VIIIdeficient plasmas was assayed by measuring the ability of the plasma to neutralize the amidolytic and anticoagulant activity of the enzyme. In the amidolytic assay, 250 Ml of plasma, 25 Al of APC (33 , U. S. Pharmacopeia U/ml final concentration) in the incubation mixtures, however, dramatically increased the background amidolytic activity of plasma proteases. This was found to be the case with normal plasma, combined Factor V/VIII-deficient plasma, and human plasma deficient in either Factor XII, Factor XI, Factor IX, high molecular weight kininogen, or prekallikrein.
In the anticoagulant assay, 1 ml of plasma and 50 ,ul of APC (50 ng/Ml of TBS:0.1% BSA) were incubated at 37°C in a plastic tube. At various times, a 100 Al-aliquot was removed and added to a borosilicate glass tube (10 X 75 mm) containing 100 Ml of normal plasma and 100 Ml of kaolincephalin (5 mg kaolin/ml cephalin) previously incubated at 370C for 4.75 min. 15 s later, 100 ,l of 25 mM CaCl2 was added and the clotting time recorded. The amount of APC activity remaining in the incubation mixture at any point was estimated from a log-log plot relating KCCT to added APC. The standard curve was constructed as follows. In a borosilicate glass tube (10 X 75 mm), 100 Ml of normal plasma and 100 Ml of kaolin-cephalin were mixed and incubated at 37°C. At 4.5 min into the incubation, 100 ,Ml of normal plasma (warmed to 37°C) was added to the tube. 15 s later, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Ml of APC (containing 25-1,000 ng enzyme dissolved in TBS:0.1% BSA) was added to the incubation mixture. 15 s later, 100 Ml of 25 mM CaCl2 was added to initiate clot formation and the KCCT was recorded. Assays were performed in duplicate. The KCCT increased linearly with 25-500 ng of APC in the assay system, but increased exponentially when greater amounts of enzyme were added to the assay. In addition, the precision between duplicate assays decreased substantially when 500-1,000 ng of APC was included in the assay. Accordingly, the initial concentration of APC in the various plasma samples tested (2,500 ng/ml) was selected to yield a clotting time in the linear portion of the standard curve when 100 Ml of the incubation mixture was added to the assay.
Demonstration of complex formation between APC and a plasma protein in various plasma samples. Covalent complex formation of APC and a plasma protein was demonstrated by SDS-PAGE of plasma-1251-APC incubation mixtures. Two different approaches were used to prepare the samples for electrophoresis. In the first approach, 225 Ml of either normal plasma or combined Factor V/VIII-deficient plasma was incubated at 37°C in a 1.4-ml snap-cap centrifuge tube with 5 Ml heparin (10 U/ml final concentration) and 25 MI of 125I-APC (14.3 ng '251-APC/Ml). At various times after the addition of the radiolabeled enzyme, 25 Ml-aliquots were removed, added to 25 Ml of 8 M urea:10% SDS, and incubated at 100°C for 2 min. A portion of the sample (10-15 Ml) was subjected to SDS-electrophoresis in 7.5% polyacrylamide gels as described.
Although this method adequately demonstrated complex formation, it nonetheless often resulted in skewed, unsymmetrical radioactive peaks due to the substantial load of protein applied to the gel. Furthermore, subsequent studies revealed that the mobility of the complex, and hence its molecular weight value, was affected by the large amount of protein applied to the gel. To overcome these problems, a second approach was devised whereby the radiolabeled enzyme and the enzyme-binding protein complex was immunoprecipitated from plasma with affinity-purified goat anti-human protein C. In this method, the various plasma samples were adsorbed beforehand with the appropriate amount of protein A-Sepharose and barium sulfate to remove endogenous IgG and protein C, respectively. Preliminary experiments demonstrated that plasma treated in this manner completely retained its ability to neutralize the amidolytic and anticoagulant activities of APC, as well as form a complex with radiolabeled APC by using the procedure described above. Thus, in a typical immunoprecipitation experiment, 200 Ml of adsorbed plasma, 10 Ml of '25I-APC, and 2 Ml of heparin (10 U/ml final concentration) were incubated in a 1.4-ml centrifuge tube at 37°C for 3 h. At (38) . The cells were loaded with antibody as follows. Two 500-Ml quantities of Pansorbin (10% suspension) were each mixed with 3 ml of 10 mM sodium phosphate (pH 7.5):100 mM NaCl:1 mM EDTA:0.1% Triton X-100, and centrifuged. The supernatants were separated from the pellet by aspiration, and the cells resuspended in 500 Ml of the above buffer. 1 7):10% Ficoll, and incubated at 100°C for 2 min. The suspension was centrifuged, and the supernatant subjected to SDS-gel electrophoresis in a 10% polyacrylamide slab gel followed by autoradiography. In the isolation procedure, 50 ml of 1 M BaCl2 were added to 1 liter of human citrated cryosupernatant, and the mixture stirred for 15 min. The precipitate was removed by centrifugation (5,000 g, 30 min). The supernatant was brought to 40% saturation with ammonium sulfate by the slow addition of salt. The mixture was stirred for 1 h and the precipitate was removed by centrifugation and discarded. The supernatant was adjusted to 70% saturation with ammonium sulfate by the slow addition of the salt. The precipitate was collected by centrifugation (5,000 g; 30 min) and dissolved in 250 ml of 50 mM Tris-HCl (pH 7.5). The protein solution was dialyzed against 20 liters of this buffer for 15 h. A precipitate that developed during dialysis was removed by centrifugation (18,000 g, 10 min).
The protein solution was applied to a heparin-agarose column (2.6 X 25 cm) previously equilibrated with 50 mM Tris-HCI (pH 7.5). The column was washed with 150 ml of equilibrating buffer containing 0.075 M NaCl. The column was then eluted with a linear gradient of NaCI generated from 250 ml of 50 mM Tris-HCI (pH 7.5):0.075 M NaCI and 250 ml of 50 mM Tris-HCI (pH 7.5):0.4 M NaCl. After the gradient, the column was eluted with 250 ml of 50 mM Tris-HCI (pH 7.5):1 M NaCI. The flow rate was 2 ml/min and 10-ml fractions were collected in plastic tubes. Those fractions containing protein that formed a complex with radiolabeled APC were pooled and dialyzed against two 4-liter quantities of 25 mM Tris-HCI (pH 8.0) for 15 h.
The retentate (70 ml) was applied to a QAE-Sephadex A-50 column (2.6 X 35 cm) previously equilibrated with 25 mM Tris-HCI (pH 8.0). After sample application, the column was washed with 200 ml of equilibrating buffer. The inhibitor was eluted from the column with a linear gradient of NaCI consisting of 600 ml of equilibrating buffer and 600 ml of equilibrating buffer containing 0.4 M NaCI. The flow rate was 1.5 ml/min and 10-ml fractions were collected in plastic tubes. Fractions from the QAE-Sephadex column containing protein that reacted with radiolabeled APC were subjected to SDS-PAGE. Only those fractions exhibiting electrophoretic homogeneity were pooled and stored at 4°C in a plastic container.
RESULTS
Inhibition of APC by normal and combined Factor VIVIII-deficient plasma. The inhibition of APC by normal plasma and combined Factor V/VIII-deficient plasma was measured in two different assays: (a) an amidolytic assay employing S-2238 as the substrate for APC, and (b) a standardized coagulant assay designed to measure the anticoagulant activity of APC.
In the anticoagulant assay, a reproducible relationship was observed between the logarithm of the clotting time and the logarithm of the APC added to the assay (Fig. 1) . Using the linear portion of this curve, we were able to determine semiquantitatively on a temporal basis the APC-anticoagulant activity after its addition to various plasma samples. The incubation mixture consisted of citrated plasma and APC at a concentration of 2.5 ,ug APC/ml plasma. Under these conditions, plasma from three unrelated patients with a combined Factor V/VIII deficiency (patients A-C) inhibited the anticoagulant activity of APC at a rate indistinguishable from that observed using normal pooled plasma (Fig. 2) . Furthermore, plasma from a Incubat/on Time (min) FIGURE 2 Inactivation of human APC in normal plasma and plasma from three unrelated patients with combined Factor V/VIII deficiency disease. Plasma (1 ml) was incubated with APC (2.5 yg/ml final concentration) at 37°C. At selected times, 0.1 ml was withdrawn and added to a glass tube containing 0.1 ml of normal plasma and 0.1 ml of kaolin-cephalin previously incubated at 37°C for 4.75 min. 15 (Fig. 2 ).
In the amidolytic assay for APC, slightly higher ratios of APC to plasma (3.3 ,g APC:ml plasma) were necessary in the incubation mixture to produce a measurable hydrolytic rate in the spectrophotometric assay. The slight difference in APC concentration notwithstanding, both normal and combined Factor V/ VIII-deficient plasma neutralized the amidolytic activity of APC at essentially the same rate as that observed in the anticoagulant assay, i.e., -50% inhibition at 30 min (data not shown). As in the anticoagulant assay, a control sample of APC retained full amidolytic activity throughout the incubation period.
As noted earlier, heparin was not included in either of our incubation systems as it (a) produced substantial increases in the background hydrolysis rate of S-2238 in the amidolytic assay, and (b) totally inhibited the anticoagulant assay at concentrations as low as 0.1 U/ ml heparin in the incubation mixture. Interestingly, the stimulation of the background S-2238 hydrolysis was observed in every human plasma sample that we tested, including prekallikrein-deficient plasma.
Complex formation of 125I-APC and a plasma-binding protein in various plasma samples. When 125I_ APC (Mr = 60,000) was incubated with either normal plasma or plasma with a combined deficiency of Factor V/VIII, '40% of the radioactivity was incorporated into a stable complex at essentially the same rate. The apparent molecular weight of the unreduced complex was 96,000 as determined by SDS-PAGE (Fig. 3A) . After reduction of the sample with mercaptoethanol, the molecular weight of the complex decreased to 80-82,000 (Fig. 3B) , suggesting that the plasma-binding protein was interacting with the heavy chain of 1251_ APC. Rate studies of reduced samples subjected to SDS-PAGE indicated that as radioactivity was incorporated into the 82,000-M, complex, the radioactivity of the 125I-APC heavy chain (M, = 40,000) decreased proportionally. The radioactivity of the light chain of 125I-APC (Mr = 22,000) remained unchanged during complex formation.
Incubation of 125I-protein C with plasma did not result in complex formation, indicating that complex formation was specific for APC. To determine if the plasma-binding protein was interacting with the active site of APC, the 125I-APC was treated with 5 mM DFP and the resulting diisopropyl (DIP)-125I-APC incu- 3 The radioactivity profile of 125I-APC and 1251-DIP-APC after incubation with plasma. Normal plasma (or Factor V/VIII-deficient plasma) was incubated with 125I-APC (A and B) or 125I-DIP-APC (C and D) for 2 h at 37°C. Radioactivity was immunoprecipitated with affinity-purified antihuman protein C, and adsorbed to S. aureus cells. The radioactivity was eluted from the cells with SDS buffer and subjected to SDS-PAGE in tube gels as described in Methods. The gels were sliced (1 mm) and the slices counted in a gamma counter. (A, C are unreduced samples; B, D are reduced samples). bated with plasma. Under these conditions, no complex formation was observed (Fig. 3, C and D) ; this supports the premise that 1251-APC was forming a complex with a plasma protein through its serine residue in the active site.
In this study, the amount of radioactivity incorporated into complex was related to the ratio of 1251-APC to plasma volume, but it never exceeded 40% of the total radioactivity in the sample at saturating levels of all plasma samples tested. This was also found to be the case when using plasma previously treated with barium sulfate and protein A-Sepharose. The degree of complex formation did not appear to be influenced by the electrophoretic system employed (continuous electrophoresis at pH 7 vs. discontinuous electrophoresis at pH 9) as was reported for complexes of antithrombin III with either Factor Xa or thrombin (39) . Furthermore, the extent of complex formation as assessed by gel filtration of 251I-APC-plasma incubation mixtures in Sephadex G-150 appeared to be -40-50%, suggesting that the degree of complex formation observed in SDS-PAGE in all likelihood did not occur as a result of dissociation during the denaturation with SDS. The reason for the low conversion of '25I-APC into enzyme-inhibitor complex is unknown at this point. Conceivably, the reduced intrinsic activity of the '251-APC for protein substrates, as noted in the KCCT assay, is one possible explanation for this behavior. Additional studies, however, are needed to clarify this issue.
Complex formation of 1251-APC and a plasma binding protein in normal plasma and plasma with a combined Factor V/VIII deficiency was found to be accelerated by the addition of heparin to the incubation mixture. The amount of radioactivity incorporated into complex was proportional to the heparin concentration up to 10 U/ml final concentration. With this concentration of heparin in the incubation mixture, the rate of complex formation was enhanced roughly fivefold over that observed in an incubation mixture without added heparin. The rate of complex formation in heparinized incubation mixtures did not appear to be affected by the addition of calcium ions and phospholipid, either alone or in combination.
The observation that heparin augmented complex formation of 125I-APC with its binding protein in plasma prompted us to reinvestigate the possibility that the plasma-binding protein of APC was either antithrombin III or a previously unrecognized derivative of antithrombin III. Earlier work from our laboratory indicated that human antithrombin III, in the presence of heparin, had no apparent effect on the amidolytic activity of APC (3). Accordingly, 125I-APC was incubated at 370C with purified human antithrombin III (inhibitor to enzyme ratios of 100-1,000:1) in the presence of TBS and heparin (10 U/ml final concentration). Under these conditions, no radioactive complex was observed by SDS-PAGE after a 3-h incubation, confirming our earlier observation. This provides strong evidence for the concept that antithrombin III was not involved in complex formation with 125j-APC. In the isolation procedure, the APC-binding protein was initially resolved from a substantial amount of protein by heparin-agarose column chromatography (Fig. 4) . Furthermore, the APC-binding protein was resolved from antithrombin III by this step, antithrombin III consistently eluted from the heparin-agarose in the 1 M NaCl elution buffer. The APC-binding protein was purified to electrophoretic homogeneity by QAE-Sephadex A-50 column chromatography (Fig. 5) . A single protein band was observed by SDS-PAGE for the APC-binding protein (Fig. 6 ) and a molecular weight of 47,000 was estimated by this technique for the unreduced protein.
After reduction with 20% 2-mercaptoethanol, the apparent molecular weight of the APC-binding protein increased to 54,000. A single protein and carbohydrate-staining band was observed in SDS-PAGE when as much as 100 ,ug of the APC-binding protein was applied to the gel, attesting to its physical homogeneity. Furthermore, SDS-gel autoradiograms of radioiodinated preparations of the purified APC-binding 2.0F 8\ ICI -I~p rotein revealed a single, intense radioactive band. Under reducing conditions routinely used in this laboratory (5-10% mercaptoethanol, 37°C, 30 min), the APC-binding protein appeared as a doublet in SDS-PAGE with apparent molecular weight values of 54,000 and 51,000. Under more rigorous reducing conditions (20% mercaptoethanol, 60°C, 30 min), the protein migrated as a single band (Mr = 54,000). In addition, the S-pyridylethylated derivative of the APCbinding protein migrated as a single band with an apparent molecular weight of 54,000.
When the APC-binding protein was subjected to alkaline disc gel electrophoresis (40), a single band was observed in 7.5% polyacrylamide gels. The mobility of the protein was remarkably low (Rf = 0.14 relative to bromophenol blue). Crossed immunoelectrophoresis of plasma and purified APC-binding protein yielded a single, coincident peak when subjected to electrophoresis in the second dimension in agarose gels containing affinity-purified antibody raised against the purified APC-binding protein. The electrophoretic mobility of the APC-binding protein clearly distinguishes it from the plasma protease inhibitors of comparable molecular weight, such as antithrombin III and a1-antitrypsin, which migrate with relatively high mobilities (41) .
The amino acid composition of the APC-binding protein is presented in Table I . The most notable features of the amino acid composition are the relatively high quantities of proline, half-cystine, and lysine. The Determined as cysteic acid according to Hirs (23) .
Determined by the method of Hugli and Moore (22) .
relatively high half-cystine content may explain, in part, the resistance of the protein to reduction. In addition, the high content of basic residues (arginine, lysine, and histidine) relative to the acidic residues (aspartic acid and glutamic acid) probably accounts for the low electrophoretic mobility of the protein observed in alkaline disc gels. The APC-binding protein is glycosylated and contains -7% neuraminic acid by weight. Purified preparations of the APC-binding protein did not form a precipitin band in Ouchterlony doublediffusion experiments with antisera raised against human antithrombin III, a1-antitrypsin, a2-antiplasmin, inter-a-trypsin inhibitor, Cl-inactivator, and a2-macroglobulin. Each of these antisera, however, formed a single precipitin band in agarose with undiluted plasma. Rabbit antisera raised against the purified APC-binding protein formed a single precipitin band when allowed to react with either purified APC-binding protein, normal plasma, or combined Factor V/ VIII deficient-plasma samples. Quantitative electroimmunoassay for the APC-binding protein in normal and Factor V/VIII-deficient plasma samples indicated that its concentration was essentially the same in all plasma samples tested (Fig. 7) . By this technique, the APCbinding protein antigen concentration was determined to be 70-80 yg/ml plasma. On the basis of these studies, the APC-binding protein did not appear to be im- from the cells by SDS-PAGE revealed that essentially all the radioactivity in the plasma supernatant represented free 125I-APC (-5% complex), whereas immunoprecipitated radioactivity represented exclusively the enzyme-binding protein complex. Fig. 9 shows the radioactivity profile of the anti-APC-binding protein immunoprecipitate before and after reduction with 10% mercaptoethanol. In the unreduced sample (Fig. 9A) , a single peak of radioactivity was observed with a corresponding molecular weight of 96,000. After reduction (Fig. 9B) Inhibition of Activated Protein Cobservation initially described by Marlar and Griffin (15) . These investigators went on to propose that this inhibitor is congenitally deficient in patients with combined Factor V/VIII deficiency disease (15) . This proposal was formulated from existing data regarding the in vitro proteolytic specificity of APC, as well as compelling evidence that plasma from four unrelated combined Factor V/VIII-deficient patients failed to inhibit the amidolytic activity of APC (15) . In this proposal, Marlar and Griffin (15) suggested that the absence of a plasma inhibitor to APC allowed for the progressive and continuous in vivo proteolytic inactivation of Factors V and VIII in these patients by unopposed APC. Their hypothesis did not include, however, a mechanism for the continuous production of APC, a condition seemingly necessary for this condition to occur, assuming there are normal biosynthetic rates for Factors V and VIII. Furthermore, it is highly interesting and statistically unusual that the four unrelated patients' plasma used in their study possessed inhibitor activity .2% of normal plasma (15) .
The data presented in this article are clearly at variance with that reported by Marlar and Griffin (15) . In this study, plasma from four patients with clinically defined combined Factor V/VIII deficiency disease inhibited the anticoagulant and amidolytic activities of human APC at essentially the same rate as that observed with normal pooled plasma. Furthermore, incubation of 125I-APC with either normal or combined Factor V/VIII-deficient plasma resulted in complex formation at essentially the same rate and final extent. Complex formation was evaluated by SDS-PAGE and was assumed to be a stable covalent complex between the radiolabeled enzyme and its putative plasma inhibitor. Complex formation was totally dependent on the integrity of the active site serine residue of APC, as DFP-treated enzyme failed to form a covalent complex in either normal or combined Factor V/VIII-deficient plasma.
The anticoagulant assay for APC provided us with an important degree of specificity not found in the amidolytic assay using S-2238, a substrate designed for thrombin assay. The hydrolysis of S-2238 after the addition of APC to plasma observed in this study, as well as that of Marlar and Griffin (15) , may not totally reflect changes in APC activity, but may in part reflect changes in the activity of other proteases or esterases that cleave this substrate. The use of the anticoagulant assay, coupled with the complex formation experiments with 125I-APC, provides two independent and specific lines of evidence that demonstrate that APC is inactivated at essentially the same rate in normal and combined deficiency plasma.
Based on its ability to form a complex with 1251-APC, as judged by SDS-PAGE, a plasma protein was purified to homogeneity by a combination of ammonium sulfate fractionation, heparin-agarose chromatography, and QAE-Sephadex chromatography. The purified protein was chemically, physically, and immunologically distinct from the well-characterized plasma serine protease inhibitors, which included antithrombin III, a1-antitrypsin, a2-antiplasmin, a2-macroglobulin, Cl inactivator, inter-a-trypsin inhibitor, and the recently described heparin cofactor II (46, 47) . The purified APC-binding protein, however, did not directly inhibit the anticoagulant or amidolytic activities of APC. Moreover, the purified binding protein failed to form a covalent complex with unlabeled preparations of APC. Our interpretation of these findings was that either the protein that we had purified had lost essentially all of its biological activity during the isolation procedure, or that we had isolated an unknown protein with a trace amount of APC inhibitor present. On the basis of (a) the amino-terminal sequence data, (b) the immunoprecipitation experiments with anti-binding protein, (c) the immunodepletion experiments, and (d) the molecular weight of the APC-binding protein as it relates to the molecular weight of the complex observed, we are reasonably certain that the former interpretation is more consistent with the experimental observations. At this point, however, we cannot categorically rule out the remote possibility that a highly immunogenic contaminant in our final preparation, with a blocked amino-terminus, is responsible for complex formation with '251-APC. This contaminant would have to constitute <0.1% of the total protein (as judged by autoradiography of labeled APC-binding protein) and would obviously have to exhibit the same electrophoretic mobility in the presence or absence of SDS as the major protein.
The reason(s) for the complete loss of APC inhibitory activity during isolation was inexplicable. Conceivably, the biological activity of the APC-binding protein is exceedingly sensitive to a particula'r condition of the isolation procedure, and the final product is rendered inactive. This possibility prompted us to develop a standardized assay for the putative APC inhibitor to evaluate loss of activity during the isolation procedure. As noted earlier, complex formation of 1251. APC with binding protein in column fractions, as monitored by SDS-PAGE, was dependent on the presence of heparin in the incubation mixture. The requirement for heparin all but eliminated the APC anticoagulant assay. Recent preliminary results using the amidolytic assay indicate that the inhibitor activity is greatly diminished after ammonium sulfate precipitation and subsequent dialysis against TBS. It is not inconceivable that, like human antithrombin III (48) , the APC inhibitor is highly unstable in dilute buffers with ionic strength levels <0.15 M. This possibility, among others such as cofactor requirements for the expression of inhibitory activity, is currently under active investigation in our laboratory.
The results of this study, taken collectively, do not support the proposal that a deficiency in APC inhibitor forms the molecular basis of the combined Factor V/ VIII deficiency disease, a proposal now generally accepted as fact (49) . Our finding of decreased VIII:CAg levels in all of our patients is in agreement with a recent report by Hultin and Eyster (50) who, to our knowledge, were the first to demonstrate a decreased VIII:CAg level in a combined Factor V/VIII-deficient patient. In addition, the Factor V antigen levels of the patients' plasma used in this study all were decreased, and paralleled their Factor V coagulant activity levels. Thus, from our observations using plasma from welldefined combined Factor V/VIII-deficient patients, it would appear that caution should be exercised in concluding that all combined Factor V/VIII-deficient patients are functionally deficient in an inhibitor directed against APC. Whether our four combined Factor V/ VIII-deficient patients reflect a unique genotype of this disorder remains to be established. It is hoped that future studies will clarify the relationship between the APC-binding protein described here and the plasma protease inhibitor involved in the physiological regulation of APC.
